Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors
Conditions:   Non Hodgkin Lymphoma (NHL);   Peripheral T-cell Lymphoma (PTCL);   Cutaneous T-Cell Lymphoma (CTCL);   Large Granular Lymphocytic Leukemia (LGL-L);   Solid Tumors Intervention:   Drug: KT333 Sponsor:   Kymera Therapeutics, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 4, 2022 Category: Research Source Type: clinical trials